Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright

ORIC +0.75%

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23 and keeps a Buy rating on the shares. The firm, which is pulling its valuation forward, says it expects the next 12 months to be “an extremely catalyst-rich period” for Oric.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ORIC:

Disclaimer & DisclosureReport an Issue

• Oric Pharmaceuticals price target raised to $17 from $16 at Citi

• Oric Pharmaceuticals Launches New 2026 ATM Share Program

• Oric Pharmaceuticals reports Q4 EPS (30c), consensus (37c)

• Oric Pharmaceuticals expects cash to fund operations into 2H 2028

• Oric Pharmaceuticals announces upcoming milestones